PLUR - Pluri Total Debt to Capital

Public company logo of Pluristem Therapeutics (PLUR)

The market valuation trend for Pluri Inc. (PLUR) based on the total debt-to-equity ratio is 0.00. Pluri Inc. (PLUR) is facing a revenue shortfall due to the slow validation of its 3D cultivation systems' effectiveness, which threatens a financial gap. The business relies on creating scalable cell platforms for therapy and nutrition while struggling with a high burn rate and a history of failed tests.

PLUR: Pluri Inc Total Debt to Capital 04/28/2023 - 10/29/2026
Core merchandise of Pluri

For biotech leader Pluri Inc. (PLUR), with its capital-intensive R&D projects in regenerative medicine, controlling the debt load is a key factor for stability. Analyzing the balance between debt and equity, we see a current value of 0.00, which reflects the proportion of total liabilities relative to net assets, determining the risk of liquidity shortages for interest payments and influencing the final fair value of the business.

Competitor analysis for Pluri Inc.

Debt to Equity Ascendis Pharma|Madrigal Pharmaceuticals Inc - Aggregate Debt to Equity|Total Debt to Capital CORT|RYTM (Rhythm Corp) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital AKRO (Akero Therapeutics)|Total Debt to Capital metsera.com MTSR|MLTX - Debt to Equity|All Debt to Shareholders' Equity Ratio CRNX (Crinetics Pharmaceuticals, Inc.)|NewAmsterdam Pharma N.V. (NAMS) - Debt to Equity|Total Debt to Equity Ratio Soleno Therapeutics Corp|FOLD (Amicus Therapeutics) - Total Debt to Capital|Total Debt to Capital 89bio.com|Total Debt to Equity Ratio AGIO (Agios Pharmaceuticals, Inc.)|GPCR (Structure Therapeutics Inc) - All Debt to Shareholders' Equity Ratio|Debt to Equity MiMedx Group MDXG|RZLT - Total Debt to Equity Ratio|Lexicon Pharmaceuticals - Total Debt to Capital|Debt to Capital mbxbio.com|ALT (Altimmune) - Total Debt to Equity Ratio|AARD: Aggregate Debt to Capital|SGMT (Sagimet) - Total Debt to Capital|Total Debt to Capital BioAge Labs, Inc|Total Debt to Capital BMEA|Debt to Equity QNCX (quincetx.com)|Debt to Equity Fractyl Health GUTS|vTv Therapeutics, Inc. (VTVT) - Debt to Capital|ATPC - Debt to Equity|SYBX: Debt to Equity|LPCN: Total Debt to Capital|MTNB - Total Debt to Capital Coefficient|Debt to Equity Spruce Biosciences, Inc.|Galecto Inc (GLTO) - Total Debt to Capital Coefficient|Debt to Equity Carmell Corp (CTCX)|Total Debt to Equity Ratio Lumos Therapeutics LUMO|Debt to Equity Organovo Holdings, Inc. ONVO|RDUS (radiuspharm.com) - Aggregate Debt to Equity